ProCE Banner Activity

First-line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced NSCLC: 3-Year Update of CheckMate 227 Part 1

Slideset Download
Conference Coverage
Chemotherapy-free treatment with first-line nivolumab and ipilimumab continues to provide durable clinical benefit to patients with advanced NSCLC, regardless of tumor PD-L1 expression.

Released: June 01, 2020

Expiration: May 31, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc.

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono